Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING: Avelumab, Axitinib, and Palbociclib in Advanced/Metastatic NSCLC
NCT03386929Phase 2Terminated
- Sponsor
- WIN Consortium
- Start
- Nov 2017
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of avelumab, axitinib, palbociclib in non-small cell lung cancer (NSCLC), sponsored by WIN Consortium. Started Nov 2017; status: terminated.
02
Drugs
avelumabaxitinibpalbociclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03386929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386929.